Since amyloid-β accumulation is a pathological feature of Alzheimer’s disease and an accelerating factor for spreading NFTs, screening for both, amyloid-β deposition and path integration—simpler and cheaper than screening for tau using PET—may be exploitable in the development of amyloid-β-targeted therapeutics. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.